In reaction to strong earnings/guidance: ZMH +11.4%, (also announced plans to combine with Biomet in Transaction Valued at $13.35 bln; expected to be double-digit accretive to Zimmer's adjusted diluted earnings per share in the first year), STC +9.7%, (light volume), ANGI +9.2%, INFN +7.7%, AAPL +7.3% (upgraded at Credit Agricole), TQNT +6.5%, ALXN +6.4%, FFIV +6.2%, FB +5.6%, ZNGA +5.4%, FTNT +5.3%, AZN +5.2%, CTXS +4.9%, (announces proposed private offering of $1.25 bln Convertible Senior Notes due 2019), AET +4.8%, LRCX +4.7%, ASGN +4.4%, TXN +3.9%, CAT +3.5%, ETFC +3.3%, YNDX +3.3%, HDSN +3.2%, (thinly traded), NOW +3.2%, PDH +3.2%, (light volume), MJN +3.1%, (light volume), DHI +3%, PTC +2.7%, (light volume), AAL +2.5%, UA +2.1%, ELY +2%, CRR +2%, SYA +1.8%, POT +1.8%, DLPH +1.8%, GM +1.8%, LOGI +1.5%, SWY +1.4%, (light volume), VZ +0.5%, DO +0.5%.
M&A related: GE +0.5% (considering Alstom takeover, according to reports out; Alstom has since denied speculation).
AAPL related tech names trading higher: CRUS +6.1%, GTAT +2.7%... Social media names higher with FB: TWTR +1.2%, LNKD +0.5%... Machinery/ag names trading higher following CAT results: TEX +2.3%, MTW +2%, CMI +0.4%
Other news: BODY +12.6% (announces review of Strategic Alternatives), VLCCF +9.3% (Knightsbridge Tankers Ltd and Frontline 2012 announced they have agreed to combine Frontline 2012's remaining fleet of 25 fuel efficient vessels with Knightsbridge), CLSN +7.5% (announces updated overall survival results from the HEAT study of ThermoDox in primary liver cancer presented at ECIO 2014; latest data sweep from large subgroup of patients shows a strong 50% improvement in overall survival for ThermoDox), RFMD +5.7% (following TQNT results), GWPH +4.3% (continued strength), PANW +4% and FEYE +1.6% (FTNT sympath), BLDP +3.8% (still checking), YELP +2.6% / TRLA +2.7% (following ANGI results), TSLA +1.9% (reports indicate co is hiring for Cali plant), SNN +1.6% ( following ZMH / Biomet deal), DDD +1.5% (still checking), BP +1% (still checking), MU +1% (positive MadMoney mention), QIHU +0.8% (Qihoo 360 Tech. forms strategic partnership with Sungy Mobile (GOMO) to target international expansion), AMGN +0.6% (Phase 3 DECISION Trial of NEXAVAR (sorafenib) in thyroid cancer refractory to radioactive iodine published in The Lancet), C +0.6% (Citigroup Board approves $1.165 bln common stock repurchase program).
Analyst comments: GT +5.1% (added to Conviction Buy list at Goldman), CIEN +3.6% ( upgraded to Buy from Neutral at UBS), AIXG +3.3% (upgraded to Neutral from Underweight at HSBC Securities), SMG +1.2% (upgraded to Outperform from Market Perform at BMO Capital), ERIC +0.5% (upgraded to Outperform from Market Perform at BMO Capital)
News 
Market Data 
Discover 
AI
